95
Participants
Start Date
August 31, 2005
Primary Completion Date
November 30, 2007
Study Completion Date
November 30, 2007
Engerix B
Standard adult dose for A1; increased adult dose for A2. Doses at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at Week 48.
Twinrix for ATN 024
Standard adult dosage, taken at Entry, Weeks 4 and 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at week 48.
Recombivax
Dosage at entry and week 24; non-responders ((\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive 3rd dose of Recombivax during weeks 48-72.
Twinrix for ATN 025
Doses at Entry and Week 24. Non-responders (\<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive a dose of Recombivax during week 48-72.
Children's Hosp Natinal Med Center, Washington D.C.
Tulane Med Center, New Orleans
Childrens Hosp of Los Angeles, Los Angeles
University of California at San Francisco, San Franciso
National Institute on Drug Abuse (NIDA)
NIH
National Institute of Mental Health (NIMH)
NIH
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
University of North Carolina, Chapel Hill
OTHER